Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full m ...

Raises Full-year GuidanceCHARLOTTE, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- SPX Technologies, Inc. (NYSE:SPXC) (“SPX”, the “Company”, “we” or “our”) today reported results for the second quarter ended June 28, 2025. Second Quarter Highlights (amounts presented for continuing operations; all comparisons against the second quarter of 2024, unless otherwise noted) Revenue of $552.4 million, up 10.2%GAAP income from continuing operations of $52.5 million, up 16.2%GAAP EPS of $1.10, up 14.6%Adjusted EPS* of $1.6 ...

IRVING, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Sow Good Inc. (Nasdaq: SOWG) (“Sow Good” or “the Company”), a trailblazer in the freeze dried candy and treat industry, will hold a conference call on Thursday, August 14, 2025, at 10:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2025. The Company will provide its financial results in a press release prior to the conference call. Date: Thursday, August 14, 2025Time: 10:00 a.m. Eastern timeRegistration Link: https://register ...

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s ...

公司财务信息 - zSpace计划于2025年8月14日美股市场收盘后发布2025年第二季度财务业绩 [1] - 公司将在财报发布当天美东时间下午5点/美西时间下午2点举行电话会议 首席执行官Paul Kellenberger和首席财务官Erick DeOliveira将出席 [2] - 电话会议可通过公司投资者关系网站的"活动与演示"栏目观看网络直播 或通过注册链接获取拨入详情 [2] 公司业务概况 - zSpace是沉浸式学习领域的领导者 专注于增强现实(AR)和虚拟现实(VR)教育解决方案 [3] - 公司解决方案应用于STEM(科学 技术 工程 数学) CTE(职业与技术教育)和职业准备课程 覆盖3500多个学区 技术中心 社区学院和大学 [3] - 总部位于加州圣何塞 拥有70多项专利 其"做中学"方案被证实能提升学习效果并提高学生考试成绩 相关研究发表于2021年《计算机辅助学习杂志》 [3] 联系方式 - 媒体联系人Amanda Austin 电话408-498-4050 邮箱press@zspacecom [5] - 投资者关系联系人Gateway Group的Cody Slach 电话9495743860 邮箱ZSPC@gateway-grpcom [5]

EDINBURG, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announced second quarter 2025 financial and operating results. Second Quarter 2025 Highlights Glo Fiber Expansion Markets1 data subscribers grew 43.1% compared to the second quarter of 2024 to approximately 76,000. Glo Fiber Expansion Markets revenue grew 40.5% compared to the second quarter of 2024 to $19.8 million. Total revenue grew 3.2% compared to the second quarter of 2024 ...

Melrose Park, IL and South Plainfield, NJ schools recognized for commitment to student success, diversity. Lincoln Tech Is a National Leader in Hands-On Career Training Students train with industry-standard equipment in a supportive learning environment. Lincoln Tech Focuses on Student Success Lincoln Tech is committed to excellence in hands-on education, career readiness and workforce development. PARSIPPANY, NJ – July 31, 2025, July 31, 2025 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corpora ...

Facephi, a leading provider and developer in the identity verification sector, reinforces digital identity protection with its new feature, Advanced Injection Defense, designed to stop deepfakes and manipulated images and videos facephi injection defense facephi injection defense BUENOS AIRES, Argentina, July 31, 2025 (GLOBE NEWSWIRE) -- In recent months, the country has witnessed how vast amounts of personal data — including sensitive information linked to official documents — have been exposed and begu ...

TAICHUNG CITY, Taiwan, July 31, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced the closing of its previously announced initial public offering of an aggregate 1,250,000 ordinary shares of the Company (the “Offering”) at a price ...

文章核心观点 SeaStar Medical宣布进行注册直接发行和私募配售融资，预计获得约440万美元资金用于一般公司用途 [1][2] 融资情况 - 公司将以每股0.887美元价格发行和出售总计4960544股普通股或普通股等价物 [1] - 同时进行私募配售，发行可购买最多4960544股普通股的未注册认股权证，行权价0.762美元，发行后即可行使，有效期五年 [1] - H.C. Wainwright & Co.担任此次发行独家配售代理，预计8月1日左右完成交易，需满足惯例成交条件 [2] - 此次发行预计毛收入约440万美元，公司计划将净收入用于一般公司用途，包括补充营运资金和资本支出 [2] 证券发行相关 - 上述普通股或普通股等价物依据2023年12月22日生效的S - 3表格上架注册声明发售，仅通过招股说明书（包括招股说明书补充文件）进行 [3] - 最终招股说明书补充文件和相关基本招股说明书将提交美国证券交易委员会（SEC），可在SEC网站获取，也可联系H.C. Wainwright & Co.获取 [3] - 未注册认股权证交易不涉及公开发行，未根据《1933年证券法》注册，相关普通股也未注册，在美国发售需符合有效注册声明或适用豁免规定 [4] 公司概况 - SeaStar Medical是商业阶段医疗保健公司，专注为面临器官衰竭和生命危险的重症患者变革治疗方案 [1][6] - 首款商业产品QUELIMMUNE（SCD - PED）于2024年获美国食品药品监督管理局（FDA）批准，是唯一获批用于治疗危重症儿科患者因败血症或脓毒症导致的危及生命的急性肾损伤（AKI）的产品 [6] - 公司选择性细胞清除设备（SCD）疗法获FDA六项治疗适应症的突破性设备认定，有望加快审批流程和改善商业推出时的报销机制 [6] - 公司正在对其SCD疗法进行关键试验，针对需要连续肾脏替代疗法的AKI成年患者，美国每年有超20万成年患者受此威胁且无有效治疗方案 [6]